In summary, we found that miR-663a suppresses the proliferation and activation of HSCs and the TGF-β/Smad pathway, highlighting that miR-663a may be used as a potential therapeutic target for hepatic fibrosis. The gene discussed is TGFB1; the disease is Hepatic fibrosis.